Bioreducible polymers for therapeutic gene delivery

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 424-439

  Lee, Young Sook ^a   Kim, Sung Wan ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

Author keywords

Bioreducible polymer; Cardiovascular disease; Diabetes; Gene; Oncolytic adenovirus; Targeting

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABLE POLYMERS; BIOMIMETICS; COVALENT BONDS; DISEASES; GENE TRANSFER; GENES; MEDICAL PROBLEMS; TOXICITY; CARDIOLOGY; GENE THERAPY;

BIOREDUCIBLE POLYMER; CARDIO-VASCULAR DISEASE; CELLULAR TOXICITIES; INTELLIGENT POLYMERS; ONCOLYTIC ADENOVIRUS; PHYSIOLOGICAL CONDITION; SUSTAINED INNOVATIONS; TARGETING;

FUNCTIONAL POLYMERS;

DENDRIMER; DNA; EXENDIN 4; GANCICLOVIR; GLUTAMATE DECARBOXYLASE; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; POLY(AMIDO ETHYLENIMINE); POLY(CYSTAMINEBISACRYLAMIDE DIAMINOHEXANE); POLY(DISULFIDE AMINE); POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; ARGINYLGLYCYLASPARTIC ACID; ERYTHROPOIETIN; GLUCAGON LIKE PEPTIDE 1; GUANIDINYLATED BIOREDUCIBLE POLYMER; HEME OXYGENASE 1; INSULIN; POLY(DISUFIDE AMINE); POLY(ETHYLENE GLYCOL) POLY(LYSINE) COPOLYMER; SURVIVIN; BIOMATERIAL; NANOPARTICLE;

ANEMIA; CARDIOVASCULAR DISEASE; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; POLYMERIZATION; SUICIDE GENE THERAPY; ADENOVIRIDAE; CARDIOVASCULAR DISEASES; CHEMISTRY; DIABETES MELLITUS, TYPE 2; GENE THERAPY; GENE TRANSFER; GENE VECTOR; NEOPLASMS; PLASMID;

ADENOVIRIDAE; BIOCOMPATIBLE MATERIALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NANOPARTICLES; NEOPLASMS; PLASMIDS; POLYMERS; RNA, SMALL INTERFERING;

EID: 84906780457     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.04.012     Document Type: Review

References (121)

1. J.M. Isner Myocardial gene therapy Nature 415 2002 234 239 (Pubitemid 34059530)
2. G.J. Nabel Genetic, cellular and immune approaches to disease therapy: past and future Nat. Med. 10 2004 135 141 (Pubitemid 38524881)
3. S.W. Kim Polymeric gene delivery for diabetic treatment Diabetes Metab. J. 35 2011 317 326
4. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360 (Pubitemid 37361705)
5. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822 (Pubitemid 38374867)
6. R.A. Petros, and J.M. DeSimone Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discov. 9 2010 615 627
7. A.S. Hoffman The origins and evolution of "controlled" drug delivery systems J. Control. Release 132 2008 153 163
8. S. Yla-Herttuala, and J.F. Martin Cardiovascular gene therapy Lancet 355 2000 213 222 (Pubitemid 30068227)
9. M. Ou, R. Xu, S.H. Kim, D.A. Bull, and S.W. Kim A family of bioreducible poly(disulfide amine)s for gene delivery Biomaterials 30 2009 5804 5814
10. A.P. Lam, and D.A. Dean Progress and prospects: nuclear import of nonviral vectors Gene Ther. 17 2010 439 447
11. T.G. Park, J.H. Jeong, and S.W. Kim Current status of polymeric gene delivery systems Adv. Drug Deliv. Rev. 58 2006 467 486 (Pubitemid 43949425)
12. T.I. Kim, and S.W. Kim Bioreducible polymers for gene delivery React. Funct. Polym. 71 2011 344 349
13. B. Jeong, Y.H. Bae, D.S. Lee, and S.W. Kim Biodegradable block copolymers as injectable drug-delivery systems Nature 388 1997 860 862 (Pubitemid 27377054)
14. W.J. Kim, and S.W. Kim Efficient siRNA delivery with non-viral polymeric vehicles Pharm. Res. 26 2009 657 666
15. E. Wagner Strategies to improve DNA polyplexes for in vivo gene transfer: will "artificial viruses" be the answer? Pharm. Res. 21 2004 8 14 (Pubitemid 38122286)
16. G. Saito, J.A. Swanson, and K.D. Lee Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv. Drug Deliv. Rev. 55 2003 199 215 (Pubitemid 36135916)
17. J.W. Yockman, A. Kastenmeier, H.M. Erickson, J.G. Brumbach, M.G. Whitten, A. Albanil, D.Y. Li, S.W. Kim, and D.A. Bull Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction J. Control. Release 132 2008 260 266
18. T. Niidome, and L. Huang Gene therapy progress and prospects: nonviral vectors Gene Ther. 9 2002 1647 1652 (Pubitemid 36104607)
19. J.W. Yockman, S.W. Kim, and D.A. Bull Women and heart disease - physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease Adv. Drug Deliv. Rev. 61 2009 863 870
20. S. Matsumoto, R.J. Christie, N. Nishiyama, K. Miyata, A. Ishii, M. Oba, H. Koyama, Y. Yamasaki, and K. Kataoka Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery Biomacromolecules 10 2009 119 127
21. D. Oupicky, A.L. Parker, and L.W. Seymour Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectors J. Am. Chem. Soc. 124 2002 8 9 (Pubitemid 34037536)
22. J.H. Brumbach, C. Lin, J. Yockman, W.J. Kim, K.S. Blevins, J.F. Engbersen, J. Feijen, and S.W. Kim Mixtures of poly(triethylenetetramine/ cystamine bisacrylamide) and poly(triethylenetetramine/cystamine bisacrylamide)-g-poly(ethylene glycol) for improved gene delivery Bioconjug. Chem. 21 2010 1753 1761
23. L.V. Christensen, C.W. Chang, W.J. Kim, S.W. Kim, Z. Zhong, C. Lin, J.F. Engbersen, and J. Feijen Reducible poly(amido ethylenimine)s designed for triggered intracellular gene delivery Bioconjug. Chem. 17 2006 1233 1240 (Pubitemid 44455332)
24. W. Suh, S.O. Han, L. Yu, and S.W. Kim An angiogenic, endothelial-cell- targeted polymeric gene carrier Mol. Ther. 6 2002 664 672 (Pubitemid 35363699)
25. J.H. Brumbach, Y.W. Lee, S.W. Kim, and J.W. Yockman Functional properties and biodistribution of poly(triethylenetetramine/cystamine bisacrylamide) and poly(triethylenetetramine/cystamine bisacrylamide)-poly(ethylene glycol) mixtures formed with nucleic acid J. Control. Release 159 2012 111 119
26. C.H. Ahn, S.Y. Chae, Y.H. Bae, and S.W. Kim Biodegradable poly(ethylenimine) for plasmid DNA delivery J. Control. Release 80 2002 273 282 (Pubitemid 34273765)
27. Y.H. Kim, J.H. Park, M. Lee, T.G. Park, and S.W. Kim Polyethylenimine with acid-labile linkages as a biodegradable gene carrier J. Control. Release 103 2005 209 219 (Pubitemid 40248573)
28. M. Ou, X.L. Wang, R. Xu, C.W. Chang, D.A. Bull, and S.W. Kim Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity Bioconjug. Chem. 19 2008 626 633 (Pubitemid 351431393)
29. T.I. Kim, T. Rothmund, T. Kissel, and S.W. Kim Bioreducible polymers with cell penetrating and endosome buffering functionality for gene delivery systems J. Control. Release 152 2011 110 119
30. P.A. Wender, W.C. Galliher, E.A. Goun, L.R. Jones, and T.H. Pillow The design of guanidinium-rich transporters and their internalization mechanisms Adv. Drug Deliv. Rev. 60 2008 452 472
31. S. Futaki Membrane-permeable arginine-rich peptides and the translocation mechanisms Adv. Drug Deliv. Rev. 57 2005 547 558 (Pubitemid 40255560)
32. M. Zorko, and U. Langel Cell-penetrating peptides: mechanism and kinetics of cargo delivery Adv. Drug Deliv. Rev. 57 2005 529 545 (Pubitemid 40255559)
33. I. Nakase, T. Takeuchi, G. Tanaka, and S. Futaki Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides Adv. Drug Deliv. Rev. 60 2008 598 607 (Pubitemid 351215576)
34. T.I. Kim, M. Ou, M. Lee, and S.W. Kim Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems Biomaterials 30 2009 658 664
35. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease Am. J. Kidney Dis. 47 2006 S11 S145
36. H.Y. Nam, Y. Lee, M. Lee, S.K. Shin, T.I. Kim, S.W. Kim, and D.A. Bull Erythropoietin gene delivery using an arginine-grafted bioreducible polymer system J. Control. Release 157 2012 437 444
37. Y. Lee, H.Y. Nam, J. Kim, M. Lee, J.W. Yockman, S.K. Shin, and S.W. Kim Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system Mol. Ther. 20 2012 1360 1366
38. T.I. Kim, M. Lee, and S.W. Kim A guanidinylated bioreducible polymer with high nuclear localization ability for gene delivery systems Biomaterials 31 2010 1798 1804
39. H.Y. Nam, K. Nam, M. Lee, S.W. Kim, and D.A. Bull Dendrimer type bio-reducible polymer for efficient gene delivery J. Control. Release 160 2012 592 600
40. S. Takae, K. Miyata, M. Oba, T. Ishii, N. Nishiyama, K. Itaka, Y. Yamasaki, H. Koyama, and K. Kataoka PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors J. Am. Chem. Soc. 130 2008 6001 6009 (Pubitemid 351620847)
41. K. Miyata, Y. Kakizawa, N. Nishiyama, A. Harada, Y. Yamasaki, H. Koyama, and K. Kataoka Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression J. Am. Chem. Soc. 126 2004 2355 2361 (Pubitemid 38295715)
42. K. Miyata, Y. Kakizawa, N. Nishiyama, Y. Yamasaki, T. Watanabe, M. Kohara, and K. Kataoka Freeze-dried formulations for in vivo gene delivery of PEGylated polyplex micelles with disulfide crosslinked cores to the liver J. Control. Release 109 2005 15 23 (Pubitemid 41737249)
43. R. Namgung, J.H. Brumbach, J.H. Jeong, J.W. Yockman, S.W. Kim, C. Lin, Z. Zhong, J. Feijen, J.F. Engbersen, and W.J. Kim Dual bio-responsive gene delivery via reducible poly(amido amine) and survivin-inducible plasmid DNA Biotechnol. Lett. 32 2010 755 764
44. C.W. Chang, D. Choi, W.J. Kim, J.W. Yockman, L.V. Christensen, Y.H. Kim, and S.W. Kim Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle J. Control. Release 118 2007 245 253 (Pubitemid 46331900)
45. H.K. Eltzschig, and T. Eckle Ischemia and reperfusion - from mechanism to translation Nat. Med. 17 2011 1391 1401
46. T.T. Rissanen, and S. Yla-Herttuala Current status of cardiovascular gene therapy Mol. Ther. 15 2007 1233 1247 (Pubitemid 46965318)
47. M. Ruponen, S. Ronkko, P. Honkakoski, J. Pelkonen, M. Tammi, and A. Urtti Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes J. Biol. Chem. 276 2001 33875 33880
48. L.V. Christensen, C.W. Chang, J.W. Yockman, R. Conners, H. Jackson, Z. Zhong, J. Feijen, D.A. Bull, and S.W. Kim Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery J. Control. Release 118 2007 254 261 (Pubitemid 46329738)
49. G. Finkenzeller, D. Marme, H.A. Weich, and H. Hug Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C Cancer Res. 52 1992 4821 4823
50. G. Wu, A.P. Mannam, J. Wu, S. Kirbis, J.L. Shie, C. Chen, R.J. Laham, F.W. Sellke, and J. Li Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF Am. J. Physiol. Heart Circ. Physiol. 285 2003 H2420 H2429
51. Y. Lee, A.N. McGinn, C.D. Olsen, K. Nam, M. Lee, S.K. Shin, and S.W. Kim Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats J. Control. Release 171 2013 24 32
52. E.R. Schwarz, M.T. Speakman, M. Patterson, S.S. Hale, J.M. Isner, L.H. Kedes, and R.A. Kloner Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation J. Am. Coll. Cardiol. 35 2000 1323 1330 (Pubitemid 30206908)
53. Y.W. Won, A.N. McGinn, M. Lee, K. Nam, D.A. Bull, and S.W. Kim Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia Biomaterials 34 2013 6229 6238
54. M. Ou, T.I. Kim, J.W. Yockman, B.A. Borden, D.A. Bull, and S.W. Kim Polymer transfected primary myoblasts mediated efficient gene expression and angiogenic proliferation J. Control. Release 142 2010 61 69
55. B.A. Borden, J. Yockman, and S.W. Kim Thermoresponsive hydrogel as a delivery scaffold for transfected rat mesenchymal stem cells Mol. Pharm. 7 2010 963 968
56. A.N. McGinn, H.Y. Nam, M. Ou, N. Hu, C.M. Straub, J.W. Yockman, D.A. Bull, and S.W. Kim Bioreducible polymer-transfected skeletal myoblasts for VEGF delivery to acutely ischemic myocardium Biomaterials 32 2011 942 949
57. L.E. Vinge, P.W. Raake, and W.J. Koch Gene therapy in heart failure Circ. Res. 102 2008 1458 1470
58. Y.W. Won, M. Lee, H.A. Kim, D.A. Bull, and S.W. Kim Hypoxia-inducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease J. Control. Release 165 2013 22 28
59. Y.W. Won, M. Lee, H.A. Kim, K. Nam, D.A. Bull, and S.W. Kim Synergistically combined gene delivery for enhanced VEGF secretion and antiapoptosis Mol. Pharm. 10 2013 3676 3683
60. S.H. Kim, J.H. Jeong, M. Ou, J.W. Yockman, S.W. Kim, and D.A. Bull Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis Biomaterials 29 2008 4439 4446
61. H.Y. Nam, J. Kim, S. Kim, J.W. Yockman, S.W. Kim, and D.A. Bull Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery Biomaterials 32 2011 5213 5222
62. H.Y. Nam, A. McGinn, P.H. Kim, S.W. Kim, and D.A. Bull Primary cardiomyocyte-targeted bioreducible polymer for efficient gene delivery to the myocardium Biomaterials 31 2010 8081 8087
63. Y.-W. Won, A.N. McGinn, M. Lee, D.A. Bull, and S.W. Kim Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier Mol. Pharm. 10 1 2013 378 385
64. S. Bergstrom, L.A. Carlson, and J.R. Weeks The prostaglandins: a family of biologically active lipids Pharmacol. Rev. 20 1968 1 48
65. C.Y. Xiao, K. Yuhki, A. Hara, T. Fujino, S. Kuriyama, T. Yamada, K. Takayama, O. Takahata, H. Karibe, T. Taniguchi, S. Narumiya, and F. Ushikubi Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4 Circulation 109 2004 2462 2468 (Pubitemid 38679568)
66. M.J. McGuire, K.N. Samli, S.A. Johnston, and K.C. Brown In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo J. Mol. Biol. 342 2004 171 182 (Pubitemid 39094513)
67. M.A. Barry, W.J. Dower, and S.A. Johnston Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries Nat. Med. 2 1996 299 305 (Pubitemid 26080650)
68. T.L. Yue, X.L. Ma, X. Wang, A.M. Romanic, G.L. Liu, C. Louden, J.L. Gu, S. Kumar, G. Poste, R.R. Ruffolo Jr., and G.Z. Feuerstein Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol Circ. Res. 82 1998 166 174 (Pubitemid 28080099)
69. H.Y. Nam, J. Kim, S.W. Kim, and D.A. Bull Cell targeting peptide conjugation to siRNA polyplexes for effective gene silencing in cardiomyocytes Mol. Pharm. 9 2012 1302 1309
70. M. Sugano, K. Tsuchida, T. Hata, and N. Makino RNA interference targeting SHP-1 attenuates myocardial infarction in rats FASEB J. 19 2005 2054 2056 (Pubitemid 41759763)
71. A.H. Chaanine, and R.J. Hajjar AKT signalling in the failing heart Eur. J. Heart Fail. 13 2011 825 829
72. J.J. Koh, K.S. Ko, M. Lee, S. Han, J.S. Park, and S.W. Kim Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice Gene Ther. 7 2000 2099 2104 (Pubitemid 32118078)
73. K.S. Ko, M. Lee, J.J. Koh, and S.W. Kim Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice Mol. Ther. 4 2001 313 316 (Pubitemid 33040515)
74. M. Lee, S. Han, K.S. Ko, and S.W. Kim Cell type specific and glucose responsive expression of interleukin-4 by using insulin promoter and water soluble lipopolymer J. Control. Release 75 2001 421 429 (Pubitemid 32727271)
75. M. Lee, S.O. Han, K.S. Ko, J.J. Koh, J.S. Park, J.W. Yoon, and S.W. Kim Repression of GAD autoantigen expression in pancreas beta-cells by delivery of antisense plasmid/PEG-g-PLL complex Mol. Ther. 4 2001 339 346 (Pubitemid 33040519)
76. K. Maasho, J. Opoku-Anane, A.I. Marusina, J.E. Coligan, and F. Borrego NKG2D is a costimulatory receptor for human naive CD8 + T cells J. Immunol. 174 2005 4480 4484
77. A. Cerwenka, and L.L. Lanier Ligands for natural killer cell receptors: redundancy or specificity Immunol. Rev. 181 2001 158 169 (Pubitemid 32703404)
78. A. Cerwenka, A.B. Bakker, T. McClanahan, J. Wagner, J. Wu, J.H. Phillips, and L.L. Lanier Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice Immunity 12 2000 721 727
79. V.J. Yao, M.G. Ozawa, M. Trepel, W. Arap, D.M. McDonald, and R. Pasqualini Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection Am. J. Pathol. 166 2005 625 636 (Pubitemid 40189057)
80. W.S. Joo, J.H. Jeong, K. Nam, K.S. Blevins, M.E. Salama, and S.W. Kim Polymeric delivery of therapeutic RAE-1 plasmid to the pancreatic islets for the prevention of type 1 diabetes J. Control. Release 162 2012 606 611
81. K.S. Blevins, J.H. Jeong, M. Ou, J.H. Brumbach, and S.W. Kim EphA2 targeting peptide tethered bioreducible poly(cystamine bisacrylamide-diamino hexane) for the delivery of therapeutic pCMV-RAE-1gamma to pancreatic islets J. Control. Release 158 2012 115 122
82. L.B. Jean, and E.U. Still studies on the physiology of secretin: III. Further studies on the effects of secretin on the blood sugar Am. J. Physiol. Heart Circ. Physiol. 91 1930 649 653
83. P.H. Kim, M. Lee, and S.W. Kim Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model J. Control. Release 162 2012 9 18
84. P.H. Kim, and S.W. Kim Polymer-based delivery of glucagon-like peptide-1 for the treatment of diabetes ISRN Endocrinol. 2012 2012 340632
85. T.I. Kim, M. Lee, and S.W. Kim Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer J. Control. Release 157 2012 243 248
86. S.W. Kim Triple combination therapy using metformin, thiazolidinedione, and a GLP-1 analog or DPP-IV inhibitor in patients with type 2 diabetes mellitus Korean Diabetes J. 34 2010 331 337
87. M. Lee, S. Oh, C.H. Ahn, S.W. Kim, B.D. Rhee, and K.S. Ko An efficient GLP-1 expression system using two-step transcription amplification J. Control. Release 115 2006 316 321 (Pubitemid 44634840)
88. S. Oh, M. Lee, K.S. Ko, S. Choi, and S.W. Kim GLP-1 gene delivery for the treatment of type 2 diabetes Mol. Ther. 7 2003 478 483 (Pubitemid 36553416)
89. P.E. MacDonald, W. El-Kholy, M.J. Riedel, A.M. Salapatek, P.E. Light, and M.B. Wheeler The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion Diabetes 51 Suppl. 3 2002 S434 S442
90. C.F. Deacon Therapeutic strategies based on glucagon-like peptide 1 Diabetes 53 2004 2181 2189 (Pubitemid 39145569)
91. Y. Lee, M.K. Kwon, E.S. Kang, Y.M. Park, S.H. Choi, C.W. Ahn, K.S. Kim, C.W. Park, B.S. Cha, S.W. Kim, J.K. Sung, E.J. Lee, and H.C. Lee Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats J. Gene Med. 10 2008 260 268 (Pubitemid 351359638)
92. S. Choi, S. Oh, M. Lee, and S.W. Kim Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes Mol. Ther. 12 2005 885 891 (Pubitemid 41614484)
93. L.R. Ranganath Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 J. Clin. Pathol. 61 2008 401 409 (Pubitemid 351518219)
94. N. Mikhail Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes Expert Opin. Investig. Drugs 17 2008 845 853 (Pubitemid 351864322)
95. D.D. Lasic Mixed micelles in drug delivery Nature 355 1992 279 280
96. K. Nam, H.Y. Nam, P.H. Kim, and S.W. Kim Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene Biomaterials 33 2012 8122 8130
97. W.P. Rowe, R.J. Huebner, L.K. Gilmore, R.H. Parrott, and T.G. Ward Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture Proc. Soc. Exp. Biol. Med. 84 1953 570 573
98. R.J. Huebner, W.P. Rowe, W.E. Schatten, R.R. Smith, and L.B. Thomas Studies on the use of viruses in the treatment of carcinoma of the cervix Cancer 9 1956 1211 1218
99. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373 376 (Pubitemid 26353341)
100. J. Kim, P.H. Kim, S.W. Kim, and C.O. Yun Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials Biomaterials 33 2012 1838 1850
101. M.A. Kay, J.C. Glorioso, and L. Naldini Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics Nat. Med. 7 2001 33 40 (Pubitemid 32095639)
102. D. Ferber Gene therapy. Safer and virus-free? Science 294 2001 1638 1642
103. J.W. Choi, J.S. Lee, S.W. Kim, and C.O. Yun Evolution of oncolytic adenovirus for cancer treatment Adv. Drug Deliv. Rev. 64 2012 720 729
104. P.H. Kim, J. Kim, T.I. Kim, H.Y. Nam, J.W. Yockman, M. Kim, S.W. Kim, and C.O. Yun Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration Biomaterials 32 2011 9328 9342
105. J. Kim, H.Y. Nam, T.I. Kim, P.H. Kim, J. Ryu, C.O. Yun, and S.W. Kim Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA Biomaterials 32 2011 5158 5166
106. P.H. Kim, T.I. Kim, J.W. Yockman, S.W. Kim, and C.O. Yun The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy Biomaterials 31 2010 1865 1874
107. J. Kim, P.H. Kim, H.Y. Nam, J.S. Lee, C.O. Yun, and S.W. Kim Linearized oncolytic adenoviral plasmid DNA delivered by bioreducible polymers J. Control. Release 158 2012 451 460
108. J. Kim, Y. Li, S.W. Kim, D.S. Lee, and C.O. Yun Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex Biomaterials 34 2013 4622 4631
109. D. Kasala, J.W. Choi, S.W. Kim, and C.O. Yun Utilizing adenovirus vectors for gene delivery in cancer Expert Opin. Drug Deliv. 11 2014 379 392
110. K.L. Berkner, and P.A. Sharp Generation of adenovirus by transfection of plasmids Nucleic Acids Res. 11 1983 6003 6020
111. H. Mok, and T.G. Park Functional polymers for targeted delivery of nucleic acid drugs Macromol. Biosci. 9 2009 731 743
112. J. Kim, S.W. Kim, and W.J. Kim PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy Oligonucleotides 21 2011 101 107
113. S.H. Chen, and G. Zhaori Potential clinical applications of siRNA technique: benefits and limitations Eur. J. Clin. Invest. 41 2011 221 232
114. S.H. Kim, M. Ou, D.A. Bull, and S.W. Kim Reductive degradation behavior of bioreducible poly(disulfide amine) for enhancing SiRNA efficiency Macromol. Biosci. 10 2010 898 905
115. Y. Dorsett, and T. Tuschl siRNAs: applications in functional genomics and potential as therapeutics Nat. Rev. Drug Discov. 3 2004 318 329 (Pubitemid 38499759)
116. C. Lavigne, and A.R. Thierry Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells Biochimie 89 2007 1245 1251 (Pubitemid 47505271)
117. J. Beloor, C.S. Choi, H.Y. Nam, M. Park, S.H. Kim, A. Jackson, K.Y. Lee, S.W. Kim, P. Kumar, and S.K. Lee Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA Biomaterials 33 2012 1640 1650
118. S.H. Kim, J.H. Jeong, T.I. Kim, S.W. Kim, and D.A. Bull VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine) Mol. Pharm. 6 2009 718 726
119. S. Florinas, H.Y. Nam, and S.W. Kim Enhanced siRNA delivery using a combination of an arginine-grafted bioreducible polymer, ultrasound, and microbubbles in cancer cells Mol. Pharm. 10 2013 2021 2030
120. B. Sangro, G. Mazzolini, M. Ruiz, J. Ruiz, J. Quiroga, I. Herrero, C. Qian, A. Benito, J. Larrache, C. Olague, J. Boan, I. Penuelas, B. Sadaba, and J. Prieto A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma Cancer Gene Ther. 17 2010 837 843
121. H.A. Kim, K. Nam, M. Lee, and S.W. Kim Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy J. Control. Release 171 2013 1 10